Pacagen
About Pacagen
Pacagen develops innovative biotechnology solutions that help neutralize pet allergens, particularly targeting common allergens from cats, dogs, and dust mites. Their software supports managing and delivering these allergen-neutralizing products effectively, improving the lives of pet owners who suffer from allergies. Proprietary allergen neutralization technology (WhiskerBlock) that reduces up to 98% of cat allergens (Fel d 1). Comprehensive product line including sprays for cats, dogs, and dust mites, plus supplements for pet food. Safe, non-toxic, and suitable for use around children, pets, and adults. Integration with e-commerce platforms like their website and Amazon for easy purchasing and product tracking. The software and products are designed for pet owners and families affected by pet allergies, veterinarians, and pet care professionals who want effective, safe solutions to reduce allergen exposure. Pacagen’s solutions help reduce allergy symptoms by neutralizing allergens in the environment and on pets, improving the quality of life for allergic individuals while allowing them to enjoy pet companionship comfortably and safely.
Company Facts
- Operating status: Active
- IPO status: Private
- Employees: 11 – 50
- Funding stage: Seed
- Last round: Seed (Jan 2025)
- Website: pacagen.com
Social Profiles
Canonical: https://fsome.com/organization/pacagen-8517828 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.